


Siemens Healthineers AG

J.P. Morgan Healthcare Conference, January 13, 2026



Safe Harbor Statement

This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context.

This webcast serves for information purposes only and the information contained herein (unless otherwise indicated) has been provided by Siemens Healthineers AG.

The information provided in connection with the webcast does not constitute or form part of, and should not be construed as, an offer of, a solicitation of an offer to buy, or an invitation to subscribe for, underwrite or otherwise acquire, any securities of Siemens Healthineers AG or any of its existing or future direct and indirect subsidiaries (subsequently "Siemens Healthineers") or any of its other affiliates, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Siemens Healthineers or of any of its affiliates or with any other contract or commitment whatsoever.

The information provided in connection with the webcast does not constitute a prospectus in whole or in part, and any decision to invest in securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) provided in connection with the webcast represent the assumptions, views or opinions of Siemens Healthineers AG, unless otherwise indicated, as of the date indicated and are subject to change without notice.

Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these assumptions, views or opinions in light of developments which differ from those anticipated.

All information not separately sourced is from internal company data and estimates. Any data relating to past performance provided in connection with the webcast is no indication as to future performance. The information provided in connection with the webcast is not intended to predict actual results, and no assurances are given with respect thereto.

The information provided in connection with the webcast has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it.

Neither Siemens Healthineers nor any of its affiliates, advisors, affiliated persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this webcast or its contents or otherwise arising in connection with this webcast.

This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction which may not lawfully be disclaimed (including in relation to fraudulent misrepresentation).

The information provided in connection with the webcast may contain statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as "expect", "forecast", "anticipate", "intend", "plan", "believe", "seek", "estimate", "will", "target" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations, plans and certain assumptions of Siemens Healthineers' management, of which many are beyond Siemens Healthineers' control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those possibly described in the respective disclosures. Should one or more of these or other risks, uncertainties or factors (e.g. events of force majeure, including but not limited to unrest, acts of war, pandemics or acts of God) materialize, plans change or should underlying expectations not occur or assumptions prove incorrect, Siemens Healthineers' management actions, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the forward-looking statement.

The information provided in connection with the webcast may include supplemental financial measures that are or may be alternative performance measures not precisely defined in the applicable financial reporting framework.

These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers' net assets, financial position and results of operations as presented in accordance with the applicable financial reporting framework. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, and therefore they may not be comparable to those included in this document.

For further explanations of our (supplemental) financial measures, please see chapter „A.2 Financial performance system“ of the combined management report and in the Notes to consolidated financial statements, Note 29 "Segment information" of the Annual Report 2024 of Siemens Healthineers. Additional information is also included in the Quarterly Statement. These documents can be found under the following internet link <https://www.siemens-healthineers.com/investor-relations/presentations-financial-publications>.

Due to rounding, numbers presented throughout this webcast and in other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

This document is an English language translation of the German document. In case of discrepancies, the German language document is the sole authoritative and universally valid version.

The information provided in connection with the webcast is provided as of the date of the webcast and is subject to change without notice.

In the event that the male form is used in this document, the information nevertheless refers to all persons.

The products/features and/or service offerings mentioned herein are not commercially available in all countries and/or for all modalities. Their future availability cannot be guaranteed. The statements by customers of Siemens Healthineers described herein are based on results that were achieved in the customer's unique setting. Because there is no "typical" hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same.

Market leader

#1

in Imaging
and Precision
Therapy

#1

in all
regions¹

90%

of leading hospitals
work with us

Global reach

>70

countries with
direct presence

3.0B

patient
touchpoints

>700K

installed
base



>200 **360**

Value
Partnerships

years in customer
contracts in FY25

€6bn

order backlog in
Value Partnerships

€2bn

p.a. in R&D
investment

>1,300 **13,000**

patent families
related to AI

R&D employees

C-level partner


Innovation leader

¹ In Imaging and Precision Therapy, market share based on Siemens Healthineers market model including external industry associations data;
Varian relating to radiation oncology market

€23.4bn
Revenue


€3.9bn
Adj. EBIT

16.5%
Adj. EBIT margin¹



Elevating Health Globally

— we have uniquely positioned ourselves to tackle the most threatening diseases



Imaging – leading with breakthrough innovations, and shaping the future of the automated imaging chain

Moving whole portfolio to photon-counting



Scaling MR DryCool technology across portfolio



Leading in molecular imaging



Automating the imaging chain




1-click

Setting new standards in breast imaging and fluoroscopy




Changing clinical pathways with photon-counting CT

Screening / early detection




Immediate clarity



No calcification, no plaque: no risk

Reduces need for diagnostic invasive angio procedures by >50%¹

Planning precisely the next step (with CT-guided PCI)



Radiation Oncology



Next generation linear accelerators for faster, more precise treatment with improved dose sparing

Interventional Oncology



3D imaging in real time to enable complete, targeted embolization

Precision Therapy



Personalized




Image guided

AI



Minimally invasive



Robotics-
and AI-
enabled

Angiography



One unified product platform – AI-powered & procedure focused – Seamless integration with device & robotics companies

Ultrasound & Mobile C-Arms




Ultrasound catheters for precise cardiac interventions with Boston Scientific partnership

Moving into adjacency pulmonology with Intuitive partnership


Image-guided, personalized and AI-enabled cancer therapies

SIEMENS
Healthineers


MR-based organs-at-risk contouring



Theranostics



AI-assisted auto-contouring




Precise planning of radiation therapy

PSMA PET confirms tumor regression

Confidently and accurately ensures radiosurgery treatment plans

Healthcare AI is a key enabler



Elevating Healthcare AI to the next level

Integrated technology across the system

Patient to image

From exam companions
to autonomous imaging






Image to report/plan

From radiology findings
to radiology report




Report/plan to treat

From auto-contouring
to instant RT planning




We have perfectly positioned ourselves to support customers to overcome their challenges



We integrate workflows from diagnosis to treatment – for faster, simplified procedures and better outcomes

Cardiovascular

CT-guided PCI¹ @Houston Methodist




Stroke

Stroke treatment @Vall d'Hebron



Neurodegenerative

NDD³ care @Link Neuroscience



Cancer

Cancer care @Alberta



Seamless integration of CT insights
– boosting cath lab workflows



Increase **procedure efficiency**
up to **27%**²

Hybrid CT & Angio-suite
– faster stroke care



30 min less **time to treatment**,
20% more patients **w/o disability**

Next-gen NDD care – tailored set-up
integrating MRI, PET & radio-tracers




Holistic **NDD care under one roof** –
from diagnosis to treatment

8-year value partnership
– democratizing cancer care



Target: **50% wait time reduction**
for cancer care⁴

Siemens Healthineers: Reliable revenue, earnings and cash compounder with sound capital deployment



FY2025

Revenue growth 5.9%


Adj. EPS €2.39


FY2026E

Revenue growth **5 to 6%**

Adj. EPS **€2.20 to 2.40**

FY2026 is a transition year – defining the baseline for double-digit EPS growth over the midterm till 2030







Q&A
